Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | AOC1 | P19801 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5768459 | 0.84 | SLC6A2 (0.51) | SLC6A2SLC6A4CYP2A6SLC6A3AOC1 | |
| SCHEMBL25910954 | 0.83 | CYP1A2 (0.42) | SLC6A2SLC6A4GAACYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL31407242 | 0.82 | SLC6A2 (0.50) | SLC6A2SLC6A4CYP2A6SLC6A3AOC1 | |
| SCHEMBL10268296 | 0.77 | — | — | |
| SCHEMBL31651986 | 0.77 | — | — | |
| SCHEMBL25378025 | 0.76 | SLC6A2 (0.44) | SLC6A2SLC6A4CYP2A6AOC1AOC3 | |
| SCHEMBL12836473 | 0.76 | SLC6A2 (0.54) | SLC6A2SLC6A4CYP2A6SLC6A3AOC1 | |
| SCHEMBL13456619 | 0.76 | SLC6A2 (0.44) | SLC6A2SLC6A4CYP2A6AOC1AOC3 | |
| SCHEMBL16547439 | 0.76 | SLC6A2 (0.54) | SLC6A2SLC6A4CYP2A6SLC6A3AOC1 | |
| Hydrochloric Acid SCHEMBL11467876 | 0.75 | CYP2E1 (0.43) | SLC6A2SLC6A4CYP2A6SLC6A3AOC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-20060160794-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY | 2006-07-20 | — | — | US | disclosed |
| EP-1638944-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000821-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160794-A1 | Tachykinin receptor antagonists | TACR1, TACR2, PROKR1 | SLC6A2 221/4885SLC6A4 348/4885CYP2A6 3531/4885 |
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | AQP1, F12, AQP3 | SLC6A2 756/4885SLC6A4 679/4885CYP2A6 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.